Swey-Shen Chen (D.Sc) is the founder of IGE Pharmaceuticals. He obtained his M.S. and D.Sc in immunology, epidemiology, and molecular biology at Harvard University, taught as Professor at the Case Western Reserve University and the University of Nebraska and Medical Center, and has worked as Principal Investigator (PI) at the La Jolla Institute and visiting PI at the Scripps Research Institute (TSRI). He invented IgE immunization, has numerous awarded patents, close to a hundred publications, and has been actively supported by the National Institute of Health (NIH) grants for his drug discovery, include a current close to 6 million USD support by the NIH for developing B-cell and T-cell based, pan-IgE asthma vaccines.
IGE Pharmaceuticals brings innovation of anti-asthma drugs to the market.
The IgE antibody system is a powerful gatekeeper for amplifying inflammation for immune defense in the lung, the GI tracts, and the skin. Elevated IgE levels to allergens and environmental pollutants however, cause allergic asthma, rhinitis, peanut and food allergy, anaphylaxis, and atopic allergic dermatitis.
We invent IgE immunization to down-regulate IgE and alleviate the above IgE-mediated allergic inflammatory disorders:
Integrating the knowledge of cellular immunology, regulatory biology, molecular biology, peptide chemistry, and protein scaffold technology, we are designing an innovative new generation of anti-allergy drugs with high efficacies and large safety margins. The treatment leads to substantially lower levels of IgE and prevents the activation of IgE sensitized mast cells. The second generation of IgE therapeutics aims at altering the natural course of allergic asthma.
IgE Pharmaceutical has two biological peptide products in the pipeline: SC-01 and SC-02.
IgE Therapeutics has analyzed the effect of the IgE protein and gene in biological systems. The drug lead, SC-01 is a biological peptide that causes down-regulation of IgE production by IgE-producing B-cells and plasma cells. SC-01 prevents IgE sensitization to mast cells and activation by allergens.
The drug lead, SC-02 is a biological peptide inserted into a protein scaffold that causes production of anti-IgE. The actively produced anti-IgE neutralizes existing IgE and protect mast cells from activation by IgE and allergens.
More than forty million individuals in the US population are afflicted with IgE-mediated allergic diseases such as allergic asthma, rhinitis, food allergy, allergic dermatitis, and anaphylactic shock. Twenty million are afflicted with allergic asthma in the US alone.
Revenues generated by prescription small molecule drugs in treating allergic asthma and rhinitis have exceeded twenty-four billion USD in 2014. The annual growth of the market is more than 10% per annum. Xolair in the form of a monoclonal antibody produced by Novartis/Genentech, is the only approved anti-asthma large molecule drug in the CBER’s biologics. In 2016, annual sales of Xolair exceeded 2.4 billion USD. Due to its high cost, the medical reimbursement cost is restricted to approximately 50,000 severe allergic asthmatic patients, and the side effect of anaphylaxis has caused an FDA black-box warning to this group of prescribed users.
The next generation of IgE pharmaceuticals targets the upstream of IgE production in order to lower IgE levels. The drugs elicit protective, mucosal cellular and humoral immune responses in the recipients resulting in lower IgE levels in the mucosal lung as well as in the circulation. Due to the technological advantage and the lower cost, these developing pan-IgE products aim at alleviating allergic asthma in all allergic asthmatic patients with mild, moderate, moderate to severe and severe allergic asthmatic syndromes